DarioHealth secured a contract with a leading New Jersey health plan covering about 1.5 million lives through its channel partner Amwell. This deal, expected to launch and generate revenue in Q1 2027, significantly expands Dario's access to large health plan populations and self-funded employer groups. It highlights the scalability of Dario's channel distribution strategy and complements previous contracts in Arizona and Florida. The integrated platform addresses multiple chronic conditions and includes provider-backed clinical care, enhancing personalized health management at scale.
DarioHealth's contract win with a major New Jersey health plan offers context for readers. For those tracking health-sector stocks, 63 of 91 US stocks rose while 25 fell on Pluang. Notable movers include Moderna (MRNA) at USD 152.00 with a 4.38% gain and 67% buy order activity, Ascendis Pharma (ASND) at USD 239.50 down 3.31%, and Sana Biotechnology (SANA) at USD 3.00 up 2.74%. Data is as of Sep 17, 2026, 18:11 WIB.
In Q3 2026, websites on Cloudflare's network blocked 13.47% of AI crawler requests, more than double the 5.98% blocked a year earlier. This rise in access denial affects how brands appear in AI-generated answers from platforms like ChatGPT, Gemini, a...
JPMorgan Asset Management (Canada) announced the final cash distributions for September 2026 for three of its ETFs traded on the Toronto Stock Exchange. Unitholders of record on October 19, 2026, will receive payments on October 23, 2026. The ETFs an...
Stillwater Critical Minerals Corp. has upgraded to the OTCQX Best Market from the OTCQB Venture Market, beginning trading under the symbol "PGEZF." This move enhances the company's visibility, liquidity, and accessibility to U.S. investors as it adva...
WasabiCard, a stablecoin-based global payment provider, engaged in key partnership discussions at TOKEN2049 Singapore 2026, focusing on white-label card issuing, global payouts, and embedded payments. The company highlighted growing demand in APAC fo...
The global next generation antibody therapeutics market is projected to increase from $5.45 billion in 2026 to $5.76 billion by 2035, growing at a CAGR of 1%. Growth is fueled by advances in biotechnology, rising demand for targeted therapies, and in...
